- Cannabis use is on the rise in the United States and other areas of the world.
- Researchers from Washington University in St. Louis found children exposed to cannabis while in the womb show increased symptoms of psychopathology such as depression and anxiety in early adolescence.
- Elevated psychopathology symptoms during adolescence can make a young person more vulnerable to developing psychiatric illness and substance misuse.
Recent research shows that recreational cannabis use is on the rise in the United States. And the United Nations Office on Drugs and Crime World Drug Report 2020 states that cannabis was the most used substance worldwide in 2018.
Although cannabis is sometimes prescribed for
A research team from Washington University in St. Louis, MO, has found evidence suggesting that children exposed to cannabis while in the womb show increased symptoms of psychopathology — including anxiety and depression — as the children become
The study appears in the journal
Research surrounding the percentage of pregnant people using cannabis is mixed.
However, other research indicates this percentage may be larger, as not all pregnant people report cannabis use to their doctor. For instance, a 2015 study found that treatment admissions for substance misuse increased from 29% to 43% for pregnant people using cannabis during their pregnancy.
However, research shows using cannabis during pregnancy can have adverse effects on a fetus, including:
Additionally, a new parent can affect their baby while nursing if they use cannabis. This older study from 1990 shows that cannabis exposure during breastfeeding can decrease a baby’s motor development at 1 year of age.
According to lead study author David Baranger, a postdoctoral scholar at Washington University, the new research builds on a
- sleeping issues
- problems with
- difficulty paying attention
That study featured data on almost 12,000 children from the Adolescent Brain and Cognitive Development Study (ABCD Study).
“In this study, we followed up with this same group of children, who are now as old as 12, to ask whether anything has changed,” Baranger explained to MNT.
“Have they improved, or gotten worse? To our surprise, we found that children with prenatal cannabis exposure still had worse mental health outcomes — things had not gotten better, nor had they gotten worse.”
Baranger said the new study suggests that elevated rates of psychopathology symptoms persist from ages 9 to 12. These symptoms include depression, anxiety, and other psychiatric conditions.
“Early adolescence is a period with increased onset of mental health disorders. That these children have a greater mental health burden at this age suggests that they may be at risk for the onset of mental health disorders in adolescence.”
– David Baranger, lead author of the new study
MNT also spoke with psychiatrist Dr. Anish R. Dube, chair of the American Psychiatric Association’s Council on Children, Adolescents and their Families, about the findings of this study and the significance of elevated rates of
“Adolescence is a developmental period of both vulnerability and opportunity in a young person’s life,” Dr. Dube explained.
“While normal emotions may be experienced more intensely in young people and they may be prone to experimentation and activities that provide immediate gratification, with a nurturing environment and developmentally appropriate support from their families and peers, they will mostly grow into healthy, well-adjusted individuals.”
“However, elevated rates of psychopathology symptoms persisting as young people transition from childhood to adolescence leave them more vulnerable to not meeting societal expectations, experiencing greater inter and intra-personal difficulties navigating these years, and ultimately may also lead to an increased risk of psychiatric illness and
– Dr. Anish R. Dube
Dr. Dube added that practitioners treating children exposed to cannabis while in the womb and who show symptoms of psychopathology may need to consider additional screening and closer follow-up of these young people for the persistence of symptoms or conversion to psychiatric illness.
“They may be more vulnerable to substance use and should be assessed accordingly and regularly,” he said.
Beyond continuing to follow this group of children as they age and develop, researchers are beginning studies to more closely study the effects of substance use on prenatal and infant development, said research team member Ryan Bogdan, Ph.D., associate professor of psychological and brain sciences and director of the BRAIN Lab at Washington University in St. Louis.
“We are currently conducting a study that is recruiting pregnant women and assessing children shortly after birth so that we may understand neonatal associations with prenatal cannabis exposure,” Dr. Bogdan said.
“We are also part of a large national study, the HEALthy Brain and Child Development (HBCD) Study, that plans to recruit approximately 7,500 pregnant women across 30 sites within the United States to better understand how all kinds of prenatal exposures, genetic factors, and early experiences may shape early development, health, and behavior in early childhood. These studies will be important to assess the effects of prenatal exposures and other factors on early child development and health,” he added.
Dr. Dube noted that he would like to see the next steps for this research to consider identifying factors associated with better outcomes despite prenatal cannabis exposure.
For example, mitigating circumstances such as specific interventions may lessen the likelihood of psychopathology symptoms. And then consider interventions early in a woman’s pregnancy that may help with cannabis use cessation.
“Further examining brain-based changes in young people entering adolescence with psychopathology symptoms and with prenatal cannabis exposure may also help explain the mechanism by which cannabis affects the developing brain and offer possible treatments,” he added.